文献速递血栓与止血

危重COVID-19疑似肝素诱导血小板减少症患者中鉴定出血小板激活免疫复合物

Platelet-activating immune complexes identified in critically ill COVID-19 patients suspected of heparin-induced thrombocytopenia.
PubMed 文献 · J Thromb Haemost · 2021-03-14

研究检测了10例疑似肝素诱导血小板减少症(HIT)的危重COVID-19患者,HIT均被排除,但6例存在FcγRIIA依赖的血小板激活,且不依赖肝素但被肝素抑制,同时检出SARS-CoV-2抗体及VWF升高,提示免疫复合物介导机制。

要点

  • 危重COVID-19疑似HIT患者中HIT均被排除,但6例存在免疫复合物介导的血小板激活。
  • 血小板激活不依赖肝素,但被治疗量和高剂量肝素抑制。
  • 所有6例血小板激活样本均检出SARS-CoV-2 RBD或刺突蛋白抗体。

核心结论

  • 本研究鉴定出血小板激活免疫复合物是危重COVID-19的一种新机制。

研究设计与样本

  • 对10例疑似HIT的危重COVID-19患者检测抗PF4/肝素抗体、5-羟色胺释放试验(SRA)及FcγRIIA阻断。

主要发现

  • 所有样本抗PF4/肝素抗体和SRA结果排除HIT。
  • 6例患者SRA显示血小板激活且被FcγRIIA受体阻断抑制,证实免疫复合物介导。
  • 血小板激活不依赖肝素,但被治疗量和高剂量肝素抑制。
  • 6例样本均阳性针对SARS-CoV-2受体结合域(RBD)或刺突蛋白的抗体。
  • 6例样本VWF抗原和活性显著升高,与4例无血小板激活的COVID-19样本无统计学差异。

关键数值与推荐

  • ADAMTS13活性未严重降低,且无ADAMTS13抑制剂,排除原发性血栓性微血管病。

临床怎么用

  • 危重COVID-19患者出现血小板减少和血栓时,应鉴别HIT并考虑免疫复合物介导的血小板激活。

局限性

  • 样本量小(10例),结论需更大规模研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Thrombocytopenia and thrombosis are prominent in coronavirus disease 2019 (COVID-19), particularly among critically ill patients; however, the mechanism is unclear. Such critically ill COVID-19 patients may be suspected of heparin-induced thrombocytopenia (HIT), given similar clinical features. OBJECTIVES: We investigated the presence of platelet-activating anti-platelet-factor 4 (PF4)/heparin antibodies in critically ill COVID-19 patients suspected of HIT. PATIENTS/METHODS: We tested 10 critically ill COVID-19 patients suspected of HIT for anti-PF4/heparin antibodies and functional platelet activation in the serotonin release assay (SRA). Anti-human CD32 antibody (IV.3) was added to the SRA to confirm FcγRIIA involvement. Additionally, SARS-CoV-2 antibodies were measured using an in-house ELISA. Finally, von Willebrand factor (VWF) antigen and activity were measured along with A Disintegrin And Metalloprotease with ThromboSpondin-13 Domain (ADAMTS13) activity and the presence of anti-ADAMTS13 antibodies. RESULTS: Heparin-induced thrombocytopenia was excluded in all samples based on anti-PF4/heparin antibody and SRA results. Notably, six COVID-19 patients demonstrated platelet activation by the SRA that was inhibited by FcγRIIA receptor blockade, confirming an immune complex (IC)-mediated reaction. Platelet activation was independent of heparin but inhibited by both therapeutic and high dose heparin. All six samples were positive for antibodies targeting the receptor binding domain (RBD) or the spike protein of the SARS-CoV-2 virus. These samples also featured significantly increased VWF antigen and activity, which was not statistically different from the four COVID-19 samples without platelet activation. ADAMTS13 activity was not severely reduced, and ADAMTS13 inhibitors were not present, thus ruling out a primary thrombotic microangiopathy. CONCLUSIONS: Our study identifies platelet-activating ICs as a novel mechanism that contributes to critically ill COVID-19.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Nazy I, Jevtic SD, Moore JC, et al. Platelet-activating immune complexes identified in critically ill COVID-19 patients suspected of heparin-induced thrombocytopenia. J Thromb Haemost. 2021. PMID: 33639037. doi:10.1111/jth.15283

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。